Related Experiment Video
Updated: Jun 23, 2026

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
Published on: March 11, 2017
Vitamin D attenuates metabolic dysfunction-associated steatotic liver disease (MASLD) and downregulates hepatic
Maiara M Cordeiro1, Naiara Cristina Lucredi1, Vanesa Oliveira Pateis1
1Department of Biochemistry, State University of Maringá (UEM), Maringá, Paraná, Brazil.
Abstract:
Metabolic dysfunction-associated steatotic liver disease (MASLD) is often linked to vitamin D deficiency. Insulin resistance (IR) plays a central role in MASLD and is tied to an abnormal activation of hepatic gluconeogenesis, contributing to the hyperglycemia found in this condition. This study evaluated whether vitamin D supplementation improves MASLD and reduces hepatic glucose production in cafeteria diet-induced obese rats. Inflammation, oxidative stress, and IR were additionally assessed both systemically and in the liver. Gluconeogenic and glycogenolytic fluxes were measured in perfused livers. Wistar rats received a cafeteria or standard diet for 60 d and remained on these diets for another 5 weeks; during this period, a subgroup in each condition received weekly vitamin D (5,600 IU/kg) by oral gavage. The cafeteria diet promoted obesity, MASLD, IR, oxidative stress, and inflammation. Obese rats displayed elevated hepatic gluconeogenesis from lactate and intensified glycogenolysis and glycolysis. Vitamin D supplementation reduced food intake and body weight gain and improved IR and glucose tolerance, changes accompanied by lower hepatic steatosis. The treatment decreased hepatic mRNA expression of nuclear factor-kappa B (NF-κB), tumor necrosis factor alpha (TNFα), and interleukin 6 (IL-6), and increased nuclear factor erythroid 2-related factor 2 (Nrf2) expression. It also upregulated vitamin D receptor, sirtuin-1, fibroblast growth factor 21 (FGF21)/β-klotho axis, and IRS-2 expression, consistent with improved hepatic insulin signaling and antioxidant defense. Vitamin D reduced the elevated gluconeogenesis and glycogenolysis in obese rats, as determined by direct metabolic flux measurements, likely due to improvements in IR and hepatic steatosis. These findings support the therapeutic potential of vitamin D for obesity-associated MASLD, with additional benefits for glycemic control. Importantly, these findings were obtained in a cafeteria diet-induced obesity model that closely resembles obesogenic human dietary patterns.
Related Concept Videos
Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Type II Diabetes II: Pathophysiology
Liver Physiology
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of 70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can also...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

